Nkarta receives U.S. FDA orphan drug designation for NKX101 for treatment of patients with AML

Clinical Impact

Dec 16

Written By Frances Benson

https://ir.nkartatx.com/news-releases/news-release-details/nkarta-receives-us-fda-orphan-drug-designation-nkx101-treatment

2021

Frances Benson

Palleon Pharmaceuticals appoints Denis Patrick to its Board of Directors

Arcellx presents continued robust long-term responses from its CART-ddBCMA Ph1 expansion trial